A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women
Sponsor: Bayer
Listed as NCT05099159, this PHASE3 trial focuses on Hot Flashes and Vasomotor Symptoms Associated With Menopause and remains completed. Sponsored by Bayer, it has been updated 28 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
28 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 23 earlier versions
-
May 2024 — Jun 2024 [monthly]
Completed PHASE3
-
Nov 2023 — May 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Austin, United States , Baden, Switzerland , Basel, Switzerland , Bellevue, United States , Berlin, Germany , Bern, Switzerland , Bernburg, Germany , Bialystok, Poland , Birmingham, United States and 93 more locations